Keros Therapeutics, Inc. (KROS): Shareholders' Equity
$303.13M
As of 2025-12-31
$262.32M
As of 2026-06-30
+3.0%
3-year compound annual growth
+3.0%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $303.13M | -47.0% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $571.55M | +72.0% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $332.21M | +19.7% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $277.42M | +14.1% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $243.17M | -7.1% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $261.72M | n/m | 2022-03-09, Balance as of period end |
| 2019-12-31 | -$19.45M | n/a | 2021-03-25, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $631.00M | +30.1% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $32.61M | n/m |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $37.21M | -47.5% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $364.05M | -13.6% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $130.34M | +41.5% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $433.90M | -22.8% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.02B | +22.5% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $307.42M | +453.3% |
Compare KROS, RCUS, AKBA, ANAB side by side · Screen every company in Pharmaceutical Preparations ↗